Thursday, December 18, 2014 3:33:16 PM
NPS's shares rose as much as 23 percent to $37.50 (23.9 pounds) on the Nasdaq. Shire's shares were up 1.3 percent on the London Stock Exchange.
The timing of a possible bid would depend on whether the U.S. Food and Drug Administration approves NPS's hormone replacement therapy Natpara, two of the people told Bloomberg.
Natpara is designed to treat low levels of the parathyroid hormone (PTH), which causes hypoparathyroidism.
The FDA is expected to decide on the drug on Jan. 24, 2015.
If approved, NPS plans to launch Natpara in the second quarter of 2015.
Although NPS is high on Shire's list of potential deals, other targets are also being considered, Bloomberg said.
Shire and NPS were not immediately available for comment.
AbbVie pulled the plug on its plan to buy Shire, blaming new U.S. tax rules aimed at curtailing tax inversion deals.
(Reporting by Devika Krishna Kumar in Bengaluru; Editing by Siddharth Cavale)
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM